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ABSTRACT 38 
Objectives: 39 
To assess the prevalence of preoperative anaemia and the impact of preoperative 40 
anaemia and blood transfusion requirement on 30- and 90-day complications in a 41 
cohort of patients undergoing robotic assisted radical cystectomy with intracorporeal 42 
urinary diversion (iRARC).  43 
 44 
Patients & methods: 45 
IRARC was performed on 166 patients between June 2011-March 2016. Prospective 46 
data was collected for patient demographics, clinical and pathological characteristics, 47 
perioperative variables, transfusion requirements and hospital length of stay. Thirty- 48 
and 90-day complications were classified according to the modified Memorial Sloan-49 
Kettering Cancer Center Clavian-Dindo system. 50 
  51 
Results: 52 
Preoperative anaemia was common (43.4%) and greatest in patients receiving 53 
neoadjuvant chemotherapy (48.6%) (p<0.001). Patients with preoperative anaemia 54 
were significantly more likely to have an Ileal conduit (p=0.033), higher cystectomy 55 
stage (≥pT3) (p=0.028) and a lower lymph node yield (p=0.031). Preoperative 56 
anaemia was not associated with increased perioperative morbidity but was 57 
associated with the need for blood transfusion (p=0.001). 58 
 59 
Blood transfusion was required in 20.4% of patients with intraoperative and 60 
postoperative blood transfusion rate was 10.2% and 13.9% respectively. The 30-day 61 
all complication rate and 30-day major complication rate was 55.4% and 15.7% 62 
respectively while 90-day all complication rate and 90-day major complication rate 63 
were 65.7% and 19.3% respectively. Intraoperative blood transfusion was not 64 
associated with increased complications but postoperative blood transfusion 65 
requirement was independently associated with perioperative morbidity: all 30 day 66 
complications (p=0.003), all 90-day complications (p=0.009) and 90-day major 67 
complications (p=0.004).    68 
  69 
Conclusion: 70 
The presence of preoperative anaemia in patients undergoing iRARC is not 71 
associated with increased surgical risk although preoperative anaemic patients were 72 
significantly more likely to require blood transfusion. Blood transfusion requirement 73 
and specifically postoperative blood transfusion is independently associated with 74 
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perioperative morbidity and is an important factor for the optimisation of 75 
postoperative outcomes.  76 
 77 
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INTRODUCTION 113 
  114 
Bladder cancer is a disease affecting predominantly elderly patients often with 115 
associated co-morbidity such as cardiovascular and respiratory disease secondary 116 
to tobacco smoking and exposure to environmental carcinogens. Radical cystectomy 117 
with urinary diversion is the gold-standard treatment for muscle invasive and highest 118 
risk bladder cancer but carries a risk of significant perioperative complications.  119 
  120 
Preoperative anaemia and blood transfusion have been shown to be associated with 121 
higher 30-day morbidity and mortality following major non-cardiac surgery.1-3 While 122 
preoperative anaemia in patients undergoing radical cystectomy has been 123 
associated with worse oncological outcomes,4 the relationship between preoperative 124 
anaemia and postoperative complications has not been investigated in the setting of 125 
radical cystectomy. 126 
  127 
Efforts to minimize perioperative complications by means of a minimally invasive 128 
approach using a robotic platform have shown limited benefits according to data 129 
from randomized controlled trials5-8 and this has been confirmed in a meta-analysis.9 130 
However, these trials were either feasibility studies, trials that were closed early prior 131 
to planned recruitment or were measuring surrogate endpoints. One advantage of a 132 
robotic approach that is consistently reported is the reduction in operative blood loss 133 
and blood transfusion requirement. Open radical cystectomy (ORC) has a reported 134 
perioperative transfusion rate of 24-83% which is significantly lower  than the 0-39% 135 
reported for RARC.10  136 
  137 
In this study, we report the prevalence of preoperative anaemia in patients 138 
undergoing radical cystectomy and investigate whether preoperative anaemia is 139 
associated with 30 and 90-day morbidity in patients undergoing robotic assisted 140 
radical cystectomy with intracorporeal urinary diversion (iRARC). A secondary aim is 141 
to explore the interplay between blood transfusion requirement, preoperative 142 
anaemia and perioperative morbidity.   143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
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PATIENTS AND METHODS 151 
 152 
Patient population 153 
Data for patients treated by iRARC were prospectively recorded to an institutional 154 
approved database. Patients included in this analysis were treated between June 155 
2011 and March 2016. During this period, 166 patients underwent iRARC and were 156 
included in the analysis. Urinary diversion was either ileal conduit or continent 157 
diversion (neobladder or Mitrofanoff) and all cases were performed by one of two 158 
surgeons. This study was registered with our institutional department and is part of 159 
an ongoing quality assurance programme (Urology2015.2). 160 
  161 
Surgical technique 162 
Our technique for iRARC has previously been previously described.11 Briefly, iRARC 163 
was performed via a standard 6 port transperitoneal approach in 27° Trendelenburg. 164 
Extent of pelvic lymph node dissection included external, internal, common iliac and 165 
obturator fossa lymph nodes. An Endocatch bag (Covidien, Dublin, Ireland) was 166 
used to retrieve specimens either from the vagina if possible in females or an iliac 167 
fossa incision in other cases. Ileal conduit formation was performed using a 15 cm 168 
segment of terminal ileum from the ileo-caecal valve which was isolated by a 169 
laparoscopic 60 mm intestinal stapler (Endo-GIA; Covidien Corp, Dublin, Ireland). 170 
Continent diversion was constructed using a 50 cm segment of terminal ileum. 171 
Uretero-ileal anastomosis was constructed using either a Bricker or Wallace 172 
anastomosis depending on surgeon preference with 6 Fr infant feeding tubes/ 173 
Bander stents which were externalized as ureteric stents.  174 
  175 
Data collected 176 
Patient demographics, clinical and pathological characteristics, perioperative 177 
variables, blood transfusion requirement, hospital length of stay (LOS) and 178 
standardised complication data were prospectively recorded. Preoperative 179 
cardiopulmonary exercise testing (CPET) was performed on 115 patients (69.3%) to 180 
determine the following results: anaerobic threshold (AT), peak oxygen consumption 181 
(Peak VO2) and minute ventilation-carbon dioxide production (VE/ VCO2). All patients 182 
were followed-up for a minimum of 90 days postsurgery.  183 
  184 
Study outcomes measured 185 
Thirty and 90-day complications were classified according to the modified Memorial 186 
Sloan-Kettering Cancer Center (MSKCC) Clavien-Dindo (CD) system.12 CD I-II and 187 
CD III-V were defined as minor and major complications respectively. Preoperative 188 
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anaemia status was defined as haemogolbin <13 g/dL in men and haemoglobin 189 
<12.0 g/dL in women in accordance with WHO criteria.13 Anaemia severity was 190 
classified as mild (men: 11.0-12.9 g/dL, women: 11.0-11.9 g/dL), moderate (men and 191 
women: 8.-0-10.9 g/dL) and severe (men and women: <8.0 g/dL).  192 
 193 
Medical complications were defined as cardiovascular, neurological, non-infective 194 
pulmonary, pre-renal failure, non-surgical related gastrointestinal (GI) complications. 195 
Infective complications were defined as the development of pyrexia (38°C) often with 196 
an attributable cause such as genitourinary, pulmonary or intra-abdominal collection.  197 
 198 
Statistical methods  199 
For continuous data, the following descriptive statistics were used: mean, median, 200 
interquartile range (IQR), standard deviation and confidence interval (95% CI). Chi 201 
square test and t-test were used for categorical and continuous variables 202 
respectively. Multivariable logistic regression was performed on variables with 203 
significance in univariate analysis. For the primary analysis all cases were included 204 
(n=166); propensity score matching was performed as a subanalysis for 121 cases.  205 
Propensity score was derived from a multivariable logistic regression model taking 206 
into account the following variables: use of neoadjuvant chemotherapy (NAC), type 207 
of urinary diversion, cystectomy stage and lymph node dissection yield. Statistical 208 
significance was set at p≤0.05. Statistical analysis was performed using SPSS v22 209 
(IBM, New York, USA). 210 
 211 
  212 
  213 
  214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
 226 
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RESULTS 227 
 228 
Patient demographics, type of urinary diversion, physiological status, prior therapy 229 
and histopathological outcomes for 166 cases stratified according to preoperative 230 
anaemia status is shown in Table 1 and blood transfusion requirement in Table 2. 231 
Overall, 43.4% (72/166) of patients were anaemic preoperatively and 20.5% (34/166) 232 
received a blood transfusion. Patients who had NAC (p<0.001), ileal conduit 233 
reconstruction (p=0.033), cystectomy stage ≥pT3 (p=0.028) and lower lymph node 234 
yield (p=0.031) were more likely to be anaemic preoperatively. The results following 235 
propensity score matching are shown in Supplementary Table 1 and confirm that 236 
preoperative anaemia was not associated with perioperative morbidity. Preoperative 237 
blood transfusion was administered in 5.4% (9/166) of patients while intraoperative 238 
and postoperative blood transfusion was performed in 10.2% (17/166) and in 13.9% 239 
(23/166) of patients respectively. Preoperative anaemic patients were significantly 240 
more likely to require intraoperative blood transfusion (p=0.004).  241 
  242 
The 30-day all complication and 30-day major complication rate was 55.4% and 243 
15.7% respectively while 90-day all complication and 90-day major complication rate 244 
was 65.7% and 19.3% respectively. GI and infective adverse events were the two 245 
most common complications affecting 43.4% and 33.7% of the patient cohort 246 
respectively. There was no relation between GI or infective events and anaemia or 247 
transfusion however, postoperative ileus, which developed in 24.1% (40/166) of 248 
patients, was associated with blood transfusion requirement (p=0.031). The 90-day 249 
mortality rate was 2.4%, and deaths were attributed to cardiac arrest in two patients, 250 
significant postoperative bleeding resulting in disseminated intravascular coagulation 251 
and ischemic bowel in one patient and one patient died from carcinomatosis 252 
secondary to a pT4N0 transitional cell carcinoma.  253 
 254 
Preoperative anaemia was not associated with 30-day or 90-day morbidity, 90-day 255 
readmission rate and median length of stay (Table 3A). No relationship was 256 
identified between severity of anaemia and complications when anaemia was further 257 
classified as mild or moderate anaemia (only one patient had severe anaemia) 258 
(Supplementary Table 2). Additionally, the propensity-score matched cohort 259 
confirmed that preoperative anaemia was not associated with perioperative morbidity 260 
(Table 3B).  261 
 262 
In contrast, blood transfusion requirement was associated with 30-day all (p=0.002) 263 
and major (0.003) complications as well as 90-day major complications (p=0.008) but 264 
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not 90-day all complications (Table 4). Median length of stay was significantly longer 265 
in patients requiring blood transfusion (p<0.001) but no difference was observed for 266 
the 90-day readmission rate. Patients who received blood transfusion were more 267 
than two fold more likely to develop a 90-day complication and three times more 268 
likely to develop a major 90-day complication (Table 4). Of interest, intraoperative 269 
blood transfusion was not associated with perioperative morbidity however, 270 
postoperative blood transfusion was significantly associated with both 30-day and 271 
90-day all and major complications (Table 5). When analysed according to 272 
complication type, postoperative blood transfusion was significantly associated with 273 
infection (52.2% vs 30.8%; p=0.044) and medical complications (43.5% vs 14.0%; 274 
p=0.001). Furthermore, postoperative blood transfusion was the only factor 275 
associated with 30-day and 90-day all and major complications in a multivariate 276 
analysis (Table 6).  277 
 278 
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DISCUSSION 303 
 304 
This is the first study to report the relationship between preoperative anaemia, blood 305 
transfusion requirement and perioperative morbidity following radical cystectomy. 306 
The prevalence of preoperative anaemia in this contemporary cohort was 43.4% and 307 
we report that anaemia alone is not associated with a higher complication rate. In 308 
contrast, we show that that requirement for blood transfusion, specifically 309 
postoperative blood transfusion, is significantly associated with an increase in 310 
complications at 30- and 90-days, as well as longer hospital LOS.   311 
 312 
The WHO defines preoperative anaemia as haemogolbin <13 g/dL in men and 313 
haemoglobin <12.0 g/dL in women.13 Anaemia can be further stratified according to 314 
severity and this has also not shown any association with perioperative 315 
complications. These results were confirmed in a propensity score matched cohort of 316 
patients. Our results are in contrast to other reports in which the relationship 317 
between preoperative anaemia and complications is established in general, vascular 318 
and orthopaedic surgery.1 In the study by Musallam et al., preoperative anaemia was 319 
associated with 30-day morbidity and mortality. This analysis was performed using a 320 
large registry dataset and such, data is not available for radical cystectomy hence we 321 
cannot discount type II error in our study. In addition, our cohort of patients were 322 
treated with a robotic approach with intracorporeal urinary diversion which 323 
represents an evolution from conventional ORC.14 However, to date there is little 324 
evidence to support any advantage for iRARC in terms of perioperative outcomes,8 325 
although early oncological outcomes for iRARC and ORC are comparable.15 It is 326 
interesting to postulate that the relationship between anaemia and perioperative 327 
outcomes for iRARC will be different for ORC and well-designed prospective 328 
randomised controlled trials will be necessary to understand this.  329 
 330 
As reported herein, patients with bladder cancer are often anaemic and as shown by 331 
others, anaemia is a poor prognostic indicator for cancer specific survival (CSS).16 332 
This study did not access CSS but we report that patients treated with NAC are 333 
significantly more likely to have preoperative anaemia. The survival benefit for NAC 334 
is established and it may be relevant to differentiate between iatrogenic (NAC 335 
induced) anaemia and the anaemia attributed to cancer (impaired erythropoietin 336 
production or haematuria). However, even when all 37 NAC cases were excluded 337 
from analysis, there remained no significant difference between preoperative 338 
anaemia and perioperative morbidity.  339 
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Although preoperative anaemia itself is not associated with perioperative morbidity, it 340 
is associated with blood transfusion requirement. Intraoperative blood transfusion 341 
specifically was associated with preoperative anaemia and there was a trend 342 
towards significance with postoperative blood transfusion. This is expected given 343 
intraoperative blood loss during cystectomy can be significant and patients with a 344 
lower preoperative haemoglobin are more likely to require blood transfusion. 345 
  346 
The current study supports that unlike preoperative anaemia, blood transfusion 347 
requirement is significantly associated with the development of postoperative 348 
complications.  All blood transfusion and specifically, postoperative blood transfusion 349 
requirement, were significantly associated with 90-day medical and infective 350 
complications. This confirms a recent report by Sui et al., in which analysis of a 351 
radical cystectomy registry dataset showed that blood transfusion requirement was 352 
associated with postoperative infection and morbidity.17 Blood transfusion, 353 
particularly transfusion of non-leucocyte depleted blood has an effect on 354 
immunomodulation.18 In patients with  bladder cancer undergoing radical 355 
cystectomy, and receiving blood transfusion, there is a reduced overall survival (HR: 356 
1.65; 95% CI, 1.08–2.52) and CSS (HR: 1.68; 95% CI, 1.04–2.70).19 Blood 357 
transfusion has been shown to increase the risk of cancer recurrence in other solid 358 
organ tumours20 and is associated with postoperative infection in trauma patients.21 359 
Immunological studies suggest that it is a reduction in natural killer cells following 360 
blood transfusion which can influence the host immune response and may be a 361 
factor responsible for the increase in postoperative bacterial infections.22 Similarly, 362 
blood transfusion is reported to be associated with organ dysfunction in intensive 363 
care treated patients.23 In orthopaedic surgery, non-transfusion optimisation of pre-364 
operative haemoglobin has been shown to reduce the requirements for blood 365 
transfusion and well as reduce postoperative infection rates.24 In our study, we found 366 
a significant linear association between number of units of blood transfused (1 ,2 or 367 
≥3 units) and both 30- and 90- day all and major complications (p<0.05). 368 
 369 
We can postulate several hypothesis why postoperative blood transfusion, but not 370 
intraoperative blood transfusion is associated with increased morbidity. The number 371 
of units transfused intraoperatively is lower than in the postoperative setting and may 372 
be a factor for the lack of association observed. Our intraoperative transfusion rate of 373 
10.2% may also be too low to detect any significant difference in perioperative 374 
complications. It is not possible to determine if postoperative transfusion is a 375 
harbinger of a pending complication or that blood transfusion itself may predispose 376 
patients to perioperative morbidity. While a preoperative prognostic factor provides 377 
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an opportunity to address the risk factor, we feel that patients requiring postoperative 378 
blood transfusion should be investigated and monitored closely due to the high risk 379 
of complications.  380 
 381 
Randomised controlled trials comparing ORC with robotic cystectomy consistently 382 
show a lower operative blood loss favouring robotic cystectomy. Following 383 
multivariate analysis, we show blood requirement transfusion is the most significant 384 
factor associated with perioperative complications. It is attractive to postulate that a 385 
robotic approach which is known to have lower estimated blood loss and 386 
requirement for blood transfusion may compensate for the increased perioperative 387 
risk attributed to preoperative anaemia.8 Similarly, other reports have suggested that 388 
impaired cardiopulmonary function measured by CPET, is associated with hospital 389 
LOS and postoperative morbidity in patients treated with ORC25 but not in iRARC 390 
treated patients.26  391 
 392 
The results of this study should be interpreted taking into account its limitations. 393 
None the less, as a single arm study, it highlights the potential for future 394 
comparisons between liberal versus restricted blood transfusion in patients 395 
undergoing radical cystectomy. Randomised controlled trials in hip27 and cardiac 396 
surgery28 have not shown any superiority of liberal blood transfusion over restricted 397 
blood transfusion. It remains important that causation between blood transfusion and 398 
complications cannot be determined but our results suggest a clear association 399 
between blood transfusion requirement and perioperative complications which is 400 
independent of preoperative anaemia. It must also be considered that transfusion 401 
requirement may be a surrogate for quality of surgery which itself could be the cause 402 
of postoperative complications. Indeed, surgical complications have been shown to 403 
be responsible for the majority of major complications following iRARC.29  404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
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CONCLUSION 416 
 417 
This study confirms that preoperative anaemia is not associated with increased 418 
perioperative complications in patients treated with iRARC. However, requirement for 419 
blood transfusion and specifically postoperative blood transfusion is strongly 420 
associate with 90-day all and major complications.  421 
  422 
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Table 1: Patient demographics, preoperative and pathological variables stratified according to preoperative anaemia status.  
 
Variable All patients  (n=166) Anaemia* (n=72) No anaemia (n=94) P value 
Sex: Male 
        Female 
125 (75.3) 
41 (24.7) 
57 (77.0) 
15 (36.6) 
68 (73.9) 
26 (63.4) 
0.312 
Age group 
<65 years 
≥65 years 
 
83 (50.0) 
83 (50.0) 
 
33 (45.8) 
29 (54.2) 
 
50 (53.2) 
44 (46.8) 
0.349 
Type of urinary diversion: 
Ileal conduit 
Continent diversion 
 
126(75.9) 
40 (24.1) 
 
61 (84.7) 
11 (15.3) 
 
65 (69.1) 
29 (30.9) 
0.020 
ASA: 
I & II 
≥III 
 
101 (60.8) 
65 (39.2) 
 
43 (59.7) 
29 (40.3) 
 
58 (61.7) 
36 (38.3) 
0.796 
BMI, mean ± SD 27.40±4.73 27.03±4.68 27.66±4.78 0.454 
CPET: 
AT, mean ± SD 
Peak VO2, mean ± SD 
VE/ VCO2, mean ± SD 
 
10.29±2.03 
15.60±4.82 
34.06±5.33 
 
10.19±1.65 
15.04±4.41 
34.64±5.80 
 
10.36±2.25 
15.99±5.07 
33.67±4.98 
 
0.639 
0.261 
0.304 
Neoadjuvant chemotherapy 51 (30.7) 35 (48.6) 16 (17.0) <0.001 
Previous pelvic radiotherapy 14 (8.4) 6 (8.1) 8 (8.7) 0.968 
Cystectomy stage 
≤pT2 
≥pT3 
 
102 (62.2) 
62 (37.8) 
 
38 (52.8) 
34 (47.2) 
 
64 (69.6) 
28 (31.1) 
0.028 
Lymph node yield, mean ± SD 14.54±9.26 12.80±7.68 15.85±10.14 0.031 
Transfusion requirement  
Intraoperative 
Postoperative 
34 (20.5) 
17 (10.2) 
23 (13.9) 
24 (33.3) 
13 (18.1) 
14 (19.4) 
10 (10.6) 
4 (4.3) 
9 (9.6) 
<0.001 
0.004 
0.068 
Blood units transfused, mean ± SD 1.03±4.32 1.57±5.66 0.60±2.81 0.152 
ASA: American Society of Anesthesiologist score; BMI: body mass index; CPET: cardiopulmonary exercise test; AT: anaerobic threshold; Peak 
VO2: maximal oxygen consumption; VE/ VCO2: minute ventilation − carbon dioxide production 
 
*men: haemogolbin <13 g/dL, women: haemoglobin <12.0 g/dL, 
Normal reference range for CPET variables: AT ≥ 11ml/kg/min; Peak VO2 ≥ 15ml/kg/min; VE/ VCO2 ≤ 32 
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Table 2: Patient demographics, preoperative and pathological variables stratified according to blood transfusion requirement.  
 
Variable All patients  (n=166) Blood transfusion (n=34) No blood transfusion (n=132) P value 
Male sex 125 (75.3) 23 (67.6) 102 (77.3) 0.246 
Age group: 
<65 years  
≥65 years 
 
83 (50.0) 
83 (50.0) 
 
20 (58.8) 
14 (41.2) 
 
63 (47.7) 
69 (52.3) 
0.249 
Type of urinary diversion: 
Ileal conduit 
Neobladder 
 
126(75.9) 
40 (24.1) 
 
629 (85.3) 
5 (14.7) 
 
97 (73.5) 
35 (26.5) 
0.151 
ASA: 
I & II 
≥III 
 
101 (60.8) 
65 (39.2) 
 
18 (52.9) 
16 (47.1) 
 
83 (62.9) 
49 (37.1) 
0.290 
BMI, mean± SD 27.40±4.73 28.06±5.71 27.28±4.57 0.512 
CPET: 
AT, mean± SD  
Peak VO2, mean± SD 
VE/ VCO2, mean± SD 
 
10.29±2.03 
15.60±4.82 
34.06±5.33 
 
10.00±1.29 
14.00±3.54 
35.09±6.53 
 
10.34±2.1 
15.88±4.97 
33.88±5.10 
 
0.503 
0.108 
0.349 
Neoadjuvant chemotherapy 51 (30.7) 20 (58.8) 14 (51.2) 0.138 
Previous pelvic radiotherapy 14 (8.4) 4 (28.6) 10 (71.4) 0.433 
Cystectomy stage: 
≤pT2 
≥pT3 
 
102 (62.2) 
62 (37.8) 
 
18 (52.9) 
16 (47.1) 
 
84 (64.6) 
46 (35.4) 
0.211 
Lymph node yield, mean± SD 14.54±9.26 14.30±8.72 14.60±9.43 0.869 
 
ASA: American Society of Anesthesiologist score; BMI: body mass index; CPET: cardiopulmonary exercise test; AT: anaerobic threshold; Peak 
VO2: maximal oxygen consumption; VE/ VCO2: minute ventilation − carbon dioxide production 
 
Normal reference range for CPET variables: AT ≥ 11ml/kg/min; Peak VO2 ≥ 15ml/kg/min; VE/ VCO2 ≤ 32 
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Table 3: A) Perioperative morbidity of patients stratified according to preoperative anaemia status. B) Propensity score matched perioperative 
morbidity of patients stratified according to preoperative anaemia status. 
 
A 
 
Variable All patients (n=166) Anaemia (n=72) No anaemia (n=94) P value 
30-day complication rate 92 (55.4) 37 (51.4) 55 (58.5) 0.360 
30-day major complication rate 26 (15.7) 10 (13.9) 16 (17.0) 0.582 
30-day infective complications 40 (24.1) 19 (26.4) 21 (22.3) 0.546 
30-day medical complications 22 (13.3) 9 (12.5) 13 (13.8) 0.802 
90-day complication rate 109 (65.7) 46 (63.9) 63 (67.0) 0.674 
90-day major complication rate 32 (19.3) 15 (20.8) 17 (18.1) 0.656 
90-day infective complications 56 (33.7) 24 (33.3) 32 (34.0) 0.924 
90-day medical complications 30 (18.1) 14 (19.4) 16 (17.0) 0.688 
90-day readmission rate 35 (21.1) 11 (15.3) 24 (25.5) 0.108 
Length of stay, median (IQR) 10.0 (8.0-15.0) 10.0 (8.0-16.0) 10.0 (8.0-14.8) 0.299 
90-day mortality 4 (2.4) 1 (1.4) 3 (3.3) 0.453 
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B 
 
Variable All patients (n=121) Anaemia (n=49) No anaemia (n=72) P value 
30-day complication rate 64 (52.9) 25 (51.0) 39 (54.2) 0.734 
30-day major complication rate 14 (11.6) 4 (8.2) 10 (13.9) 0.334 
30-day infective complications 28 (23.1) 11 (22.4) 17 (23.6) 0.882 
30-day medical complications 14 (11.6) 4 (8.2) 10 (13.9) 0.334 
90-day complication rate 77 (63.6) 32 (41.6) 45 (62.5) 0.753 
90-day major complication rate 20 (16.5) 9 (18.4) 11 (15.3) 0.653 
90-day infective complications 39 (32.3) 15 (30.6) 24 (33.3) 0.753 
90-day medical complications 21 (17.4) 8 (16.3) 13 (18.1) 0.805 
90-day readmission rate 28 (23.1) 9 (18.4) 19 (26.4) 0.304 
Length of stay, median (IQR) 10.0 (8.0-15.0) 11.0 (8.0-16.0) 10.0 (8.0-14.0) 0.330 
90-day mortality 2 (1.7) 1 (2.0) 1 (1.4) 0.782 
 
 
*men: haemogolbin <13 g/dL, women: haemoglobin <12.0 g/dL 
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Table 4: Perioperative morbidity of patients stratified according to blood transfusion requirement. 
 
 
Variable All patients  (n=166) Blood transfusion (n=34) No blood transfusion (n=132) P value 
30-day complication rate 92 (55.4) 27 (79.4) 65 (49.2) 0.002 
30-day major complication rate 26 (15.7) 11 (32.4) 15 (11.4) 0.003 
30-day infective complications 40 (24.1) 12 (35.3) 28 (21.2) 0.087 
30-day medical complications 22 (13.3) 9 (26.5) 13 (59.1) 0.011 
90-day complication rate 109 (65.7) 27 (79.4) 82 (62.1) 0.058 
90-day major complication rate 32 (19.3) 12 (35.3) 20 (15.2) 0.008 
90-day infective complications 56 (33.7) 15 (44.1) 41 (31.1) 0.151 
90-day medical complications 30 (18.1) 12 (35.3) 18 (13.6) 0.003 
90-day readmission rate 35 (21.1) 8 (23.5) 27 (20.5) 0.695 
Length of stay, median (IQR) 10.0 (8.0-15.0) 14.0 (8.3-25.0) 10.0 (8.0-14.0) <0.001 
90-day mortality 4 (2.4) 1 (2.9) 3 (2.3) 0.821 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
 
 
Table 5: Univariate analysis to evaluate 30-day and 90-day complications.  
 
 
 
 
 
 
 
 
 
 
 
 
BMI: body mass index; ASA: American Society of Anesthesiologist score; AT: anaerobic threshold; Peak VO2: maximal oxygen consumption; VE/ 
VCO2: minute ventilation − carbon dioxide production; NAC: neoadjuvant chemotherapy; IC: ileal conduit  
*men: haemogolbin <13 g/dL, women: haemoglobin <12.0 g/dL 
 
 
 
Variable All 30-day complications 30-day major complications All 90-day complications 90-day major complications 
Preoperative OR (95%) P value OR (95%) P value OR (95%) P value OR (95%) P value 
Gender: male vs female                1.38 (0.68-2.80) 0.371 2.86 (0.81-10.06) 0.090 1.31 (0.63-2.72) 0.466 3.83 (1.10-13.31) 0.025 
Age <65 vs ≥ 65 yrs  1.05 (0.57-1.94) 0.876 0.47 (0.20-1.13) 0.088 0.69 (0.36-1.31) 0.253 0.53 (0.24-1.18) 0.115 
BMI <25 vs ≥25 1.54 (0.74-3.21) 0.244 1.06 (0.37-3.00) 0.920 0.60 (0.27-1.32) 0.199 0.89 (0.34-2.29) 0.804 
ASA: I & II vs ≥III 1.90 (1.00-3.60) 0.048 1.42 (0.61-3.31) 0.410 1.02 (0.53-1.97) 0.950 1.28 (0.59-2.80) 0.533 
AT  0.95 (0.80-1.12) 0.553 1.00 (0.79-1.26) 0.990 0.93 (0.78-1.10) 0.375 1.02 (0.83-1.26) 0.850 
Peak VO2  1.01 (0.94-1.08) 0.824 1.05 (0.96-1.14) 0.320 1.03 (0.95-1.11) 0.507 1.06 (0.97-1.15) 0.192 
VE/ VCO2  0.98 (0.92-1.05) 0.582 0.99 (0.90-1.08) 0.765 0.96 (0.90-1.03) 0.213 0.98 (0.90-1.06) 0.591 
NAC: yes vs no 0.64 (0.33-1.24) 0.181 1.83 (0.78-4.33) 0.163 1.07 (0.53-2.14) 0.856 1.73 (0.78-3.84) 0.177 
Preoperative anaemia: yes vs no* 
 
0.75 (0.40-1.39) 0.360 0.79 (0.33-1.85) 0.582 
 
 
0.87 (0.46-1.66) 0.674 1.19 (0.55-2.59) 0.656 
Intraoperative 
Transfusion: yes vs no                       5.11 (1.99-13.16) <0.001 3.73 (1.52-9.15) 0.003 2.35 (0.95-5.80) 0.058 3.06 (1.31-7.14) 0.008 
Intraoperative transfusion 2.13 (0.71-6.34) 0.168 1.78 (0.53-5.95) 0.346 1.29 (0.43-3.85) 0.652 1.33 (0.40-4.39) 0.639 
Postoperative transfusion 23.6 (3.1-179.77) <0.001 4.77 (1.79-12.68) 0.001 6.56 (1.48-29.01) 0.005 4.23 (1.65-10.85) 0.002 
Type of diversion: IC vs continent                                1.51 (0.73-3.14) 0.263 1.20 (0.46-3.09) 0.714 3.10 (1.27-7.56) 0.010 1.30 (0.55-3.10) 0.553 
Previous pelvic radiotherapy: yes vs 
no 
0.81 (0.27-2.42) 0.705 1.53 (0.40-5.91) 0.535 0.36 (0.12-1.09) 0.060 0.68 (0.144-3.19) 0.621 
Cystectomy stage: ≤pT2 vs ≥pT3                                   0.81 (0.43-1.53) 0.512 0.69 (0.28-1.70) 0.420 0.62 (0.32- 1.20) 0.151 1.16 (0.53-2.55) 0.714 
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Table 6: Multivariate analysis to evaluate perioperative morbidity. 
 
 OR (95%) P value 
All 30-day complications 
ASA: I & II vs ≥III 1.49 (0.77-2.88) 0.233 
Postoperative transfusion: yes vs no                        9.46 (2.13-42.00) 0.003 
90-day all complications 
Type of diversion: IC vs continent                                3.43 (1.40-8.44) 0.007 
Postoperative transfusion: yes vs no                        7.39 (1.65-33.1) 0.009 
90-day major complications  
Gender: male vs female               0.45 (0.17-1.23) 0.121 
Postoperative transfusion: yes vs no                      4.2 (1.62-10.97) 0.004 
 
 
 
 
 
